Introduction
MicroRNAs are a class of small noncoding RNAs of 19~25 nt (usually ~22 nt). Their genes can be located separately or in clusters in noncoding regions of the genome or in introns of coding genes [1] . The primary transcripts of most microRNAs (pri-miRNAs) are generated by RNA polymerase II [2] , and they have a 5′ cap and a 3′ polyA tail [3] . The pri-miRNAs are then processed by Drosha, an RNase III superfamily member, in the nucleus to form an 80~100 nt hairpin precursor. Precursor miRNAs are exported by exportin-5 and cleaved by Dicer in the cytoplasm, releasing the mature miRNAs [4] [5] [6] [7] [8] [9] . Mature microRNAs usually function by targeting the 3′ UTR of mRNAs, which leads to translation inhibition or target degradation [10] .
In hematopoiesis, as well as in leukemia, there is increasing evidence that microRNAs have critical functions [11] . Several hematopoietic specific microRNAs, including miR-181, miR-142 and miR-223, were identified by Chen and his colleagues [12] . They found that after overexpressing miR-142 or miR-223 in Lin -hematopoietic progenitors, the percentage of T cells derived from these progenitor cells increased significantly. Furthermore, Fazi et al. found that miR-223 expression was activated by CEBP-α and inhibited by NFI-A through a competitive binding mechanism. Meanwhile, miR-223 could target NFI-A mRNA and repress its translation, completing a mini regulatory circuit [13] . miR-223 was shown to have crucial functions in promoting granulocytic [14, 15] and suppressing erythrocytic differentiation [16] , respectively. Another study showed that the expression of miR-223 was also regulated by the myeloid/erythroidspecific transcriptional regulators PU1 and GATA1, where GATA1 and PU1 functioned as a transcriptional repressor and activator [17] , respectively.
LMO2 and CEBP-β are both crucial regulators of hematopoiesis. CEBP-β belongs to the family of basic leucine zipper (bZIP) transcription factors, and its main function has been implicated to be in control of myeloid differentiation [18] . Forced expression of CEBP-α/β can even re-program committed B or T cell progenitors into macrophages [19, 20] .
The lmo2 gene was first cloned from an acute T lymphocyte leukemia (T-ALL) patient with an (11;14) (p13;q11) translocation [21] , and it was generally considwww.cell-research.com | Cell Research Wei Sun et al. 1159
npg ered as a proto-oncogene in T cells [22] [23] [24] . It was later shown to be expressed in all hematopoietic cells except mature T lymphocytes, but its expression could be detected in precursor T cells and it was down-regulated during the double-negative (DN) stage in T-cell development [25] . Transgenic studies showed that lmo2 mainly functions in early hematopoiesis and embryonic angiogenesis [26, 27] . A Lmo2 null mutation in mice led to the failure of yolk sac erythropoiesis and subsequent embryonic lethality around E10.5 [28] . In contrast, over-expression of LMO2 caused T-cell development arrest and a T-ALLlike syndrome [29] . This finding was supported by two reported cases of gene therapy for X-SCID, in which the therapeutic lentivirus vector inserted into the LMO2 locus, resulting in abnormal LMO2 expression and T-ALL syndrome [30] . Interestingly, in T-cell-specific lmo2 conditional knockout mouse models, the cell-specific deletion of lmo2 showed no prominent effects on T-cell development [31] .
The lmo2 gene encodes two isoforms of protein product, LMO2-L and LMO2-S [32, 33] . LMO2-L and -S have their own promoters, and their expressions are stringently regulated in hematopoietic cells [34] [35] [36] . Both LMO2-L and -S are transcriptional regulators: they function as bridge molecules to assemble complexes with their partners, including LDB1, GATA1, TAL1 and E47. These complexes regulate gene expression by recognizing and binding to specific DNA sequences of their targets [37, 38] .
Although there is increasing evidence that miR-142, miR-223, LMO2 and CEBP have pivotal roles in hematopoiesis, their exact regulatory patterns and functional relationships are still unclear. In this study, we found a similar function for both the LMO2-L and -S isoforms in down-regulating miR-142 expression. We also found that miR-223 could negatively regulate both LMO2 isoforms transcriptionally and post-transcriptionally, the former of which was mediated by CEBP-β. Taken together, our data reveal a novel miR-223-CEBP-β-LMO2-miR-142 regulatory pathway and suggest that miR-223 achieves its function of arresting hematopoietic cell proliferation by up-regulating the expression of miR-142 through this pathway. ( Figure 1A) . The real-time PCR analysis showed exact fold changes of miR-142 expression in these three cell types ( Figure 1B) . Figure 1 showed a regulation of miR-142 expression by miR-223. However, until now, the transcription start site of miR-142 has not been confirmed. Using the 5′ RACE protocol, a DNA fragment of about 300 bp was amplified from RNAs from K562 miR-223 cells where miR-142 primary transcripts were relatively abundant (Figure 2A , sample lane). Interestingly, there was no specific band from the sample of K562 cells (Figure 2A , NC lane). The 300 bp DNA fragment was then cloned into the pMD-19T vector and sequenced. According to the alignment between the sequence of this fragment and the miR-142 genomic locus, the exact transcription start site was located 308 bp upstream from the 5′ end of the miR-142 precursor ( Figure 2B ). On the other hand, a poly-A signal was also found about 730 bp downstream Figure 2C ) and this site was conserved in the corresponding location in the mouse genome (data not shown). These results indicate that the primary transcript of miR-142 is about 750 bp in length, and that there are no introns in this gene. In our previous study, it was demonstrated that LMO2 could negatively regulate the expression of miR-142 by binding to a typical LMO2 binding site located in the upstream region of the miR-142 locus [39] . In addition, the TESS online transcription element search system (http:// www.cbil.upenn.edu) revealed that there are two typical CEBP-β sites in the 2 kb promoter region, as indicated in Figure 2D . However, Luciferase reporter assays showed that both reporters (N1, 2 320 bp in length and N6, 1 154 bp in length) displayed reduced, rather than increased, activity when co-transfected with a CEBP-β expression plasmid (full length CEBP-β with the trans-activation domain at the N-terminus) in K562 cells ( Figure 2D ). Realtime PCR analysis showed that the endogenous miR-142 level was also decreased after transient over-expression of CEBP-β in K562 cells ( Figure 2E ). It is widely accepted that the full-length form of CEBP-β functions as a transcriptional activator, thus it seems unlikely that it could down-regulate the transcription of miR-142 directly. Therefore, the negative regulatory function on miR-142 by the full-length form of CEBP-β might be mediated by other factor(s).
Results

Over
The expression of CEBP-β was down-regulated posttranscriptionally by miR-223
Directly or not, CEBP-β was shown to be involved in the regulation of miR-142. Manual alignment showed that the core binding sequence of miR-223 (2-7 nt) matched well with the 3′ UTR sequence of CEBP-β mRNA ( Figure 3A ). When the pGL3-control-CEBP-β-3′ UTR reporter was co-transfected with the miR-223 expression vector into HEK293 cells, there was a 40% decrease in the Luciferase activity compared to the cells that were co-transfected with the reporter and the scrambled plasmid ( Figure 3B ). To further confirm this result, we generated pGL3-control-CEBP-β-3′ UTR point mutant. After mutating the TG in core binding sequence to AC, as shown in Figure 3A , the inhibition effect of miR-223 on this reporter was eliminated ( Figure 3B ). In addition, western blot analysis showed that the level of CEBP-β protein was much lower in K562 miR-223 cells than in unmodified K562 cells ( Figure 3C ). This result shows that CEBP-β is a target of miR-223 and suggests an miR-223-CEBP-β-miR-142 regulatory pathway.
miR-223 down-regulated both the LMO2-L and -S isoforms transcriptionally and post-transcriptionally
Interestingly, when we examined the expression levels of the LMO2-L/-S isoforms, it was found that in K562
miR-223 cells, the mRNA levels of both LMO2-L and -S decreased significantly ( Figure 4A ). Real-time PCR analysis showed that LMO2-L level decreased by about 5-fold while LMO2-S decreased by about 10-fold in K562
miR-223 cells compared to unmodified K562 cells ( Figure 4B) . Notably, the Sanger miRNA database (http:// microrna.sanger.ac.uk) and the Targetscan online prediction program (http://www.targetscan.org) both show that LMO2 is a post-transcriptional target of miR-223 [16] ( Figure 4C ). As the 3′ UTR in LMO2-L and LMO2-S mRNAs are identical, Luciferase reporter assays showed that miR-223 negatively regulated both the LMO2-L and the LMO2-S isoforms at a post-translational level ( Figure  4D ). Furthermore, in K562 cells transiently over-expressing LMO2, regardless of the isoform, we observed the decreased expression of miR-142. Accordingly, si-LMO2 showed the opposite effect ( Figure 4E ), suggesting that the up-regulation of miR-142 by miR-223 is mediated by LMO2.
CEBP-β up-regulated the expression of both LMO2-L and LMO2-S
Considering that miR-223 negatively regulated CEBP-β directly in a post-transcriptional manner and down-regulated LMO2-L/-S at the transcriptional level, we sought to determine whether CEBP-β mediated the transcriptional regulation from miR-223 to the LMO2 isoforms. To address this issue, the proximal promoter of LMO2-L (from -384~+119) and the promoter of LMO2-S (from -294~+332) were cloned from the normal human genome and inserted into a pGL4-based Luciferase reporter vector. In co-transfection assays with the CEBP-β expression vector, both LMO2-L and -S promoter activities were increased significantly in the presence of CEBP-β ( Figure 5A ). TESS online prediction program (http://www.cbil.upenn.edu) showed that there are one CEBP-β binding site in LMO2-L proximal promoter and two in LMO2-S promoter ( Figure 5B , core binding sequences are listed in the blue box). When the CEBP-β site was mutated in the proximal promoter of LMO2-L (TATTGC→TAGAGC), the CEBP-β-mediated up-regulation of the promoter's activity was eliminated. Similarly, mutation of either CEBP-β site in the promoter of LMO2-S (TGATGGAAT→TGATGGGGT or GCAATT→GCGGTT, as marked in Figure 5B ) reduced the CEBP-β-mediated activity of the promoter modestly, while mutation of both of these two sites eliminated this activity ( Figure 5B ). In chromatin immunoprecipitation (ChIP) assays using specific scanning primers (pLMO2-L primers and pLMO2-S primers), both of the promoters of LMO2-L and LMO2-S could be detected in the anti-CEBP-β precipitant ( Figure 5C ). In addition, transient over-expression of CEBP-β in the myeloid leukemia cell line U937 increased the mRNA levels of both LMO2-L and -S, as detected by real-time PCR ( Figure 5D ). These data suggest that down-regulation of the LMO2 isoforms at the transcriptional level by miR-223 is mediated by CEBP-β, and LMO2 down-regulation further mediates miR-142 expression.
miR-223 and miR-142 similarly attenuated cell proliferation in the myeloid cell line K562
Some reports have indicated that miR-223 can affect cell growth in hematopoiesis [12, 15] . According to the regulation pattern from miR-223 to miR-142 that we showed above, we hypothesized that the function of miR-223 might be achieved through miR-142. To address this issue, all K562 cells with modifications of miR-142 or miR-223 (K562 miR-142 and K562 miR-223 cells ), or the mediators involved in their regulation pathway (K562
LMO2-L , K562 LMO2-S and K562 CEBP-β cells), were used for proliferation assays. Proliferation of the K562, K562 miR-142 and K562 miR-223 cells was first examined using the CCK8 assay. The cell number-absorbance standard curve of each cell type was established and then the absorbance of each sample was converted into cell number according to the standard curves. The graph in Figure 6A shows the growth curve of each cell type. It can be seen that K562
miR-142 and K562 miR-223 cells had decreased numbers of cells compared to unmodified K562 cells after a 48 h culture, and that this was more significant at 72 h, indicating that proliferation was attenuated in K562 , K562
LMO2-L , K562 LMO2-S and K562 CEBP-β cells was also examined. We showed earlier that LMO2-L, LMO2-S and CEBP-β could down-regulate miR-142 levels while si-LMO2 could up-regulate miR-142 levels. Accordingly, the percentage of cells undergoing proliferation in K562 si-LMO2 cells was about 5% less than in the control (unmodified K562 cells and K562 cells transfected with pcDNA6B empty vector) and was similar to that in K562 miR-142 and K562 miR-223 cells. However, the percentage of cells undergoing proliferation increased (≥ 5%) in K562 LMO2-L , K562
LMO2-S and K562 CEBP-β cells compared to the control ( Figure 6B ). Figure 6C shows representative FACS results of each of the cell types. There were obvious nonproliferating subgroups (BrdU negative, PI positive) in K562 miR-142
, K562
miR-223 and K562 si-LMO2 cells compared to 
Discussion
Increasing evidence shows that microRNAs are involved in controlling hematopoiesis. Considering the mechanism of miRNA regulation, they should function indirectly in this process through inhibiting the expression of their targets. There have been some reports of the functions of miRNAs and their related target genes in hematopoiesis, such as kit regulation by miR-221 and -222 in erythrocyte development [40] , and HOXA1 regulation by miR-10a and MAFB regulation by miR-130a in megakaryocyte development [41] . As suggested by some reports, each miRNA has several targets [42] . Some of the targets may be crucial transcriptional regulators, such as CEBP-β and LMO2. Thus, changes in miRNA expression might cause a cascade of gene expression changes that could in turn affect hematopoiesis. Some miRNAs may also be involved in the regulatory network as the indirect regulatory targets of other miRNAs: the regulation of miR-142 by miR-223 is such an example, suggesting that expression of microRNAs can also be regulated by other microRNAs.
miR-223 and miR-142 were initially reported to have a similar function in promoting T-cell development [12] . Interestingly, the expression of miR-223 in the T-cell lin-A B eage is barely detectable, while the expression of miR-142 is somewhat detectable in all hematopoietic lineages [43] . miR-223 is abundantly expressed in myeloid cells, and until now, all revealed targets of miR-223 were those involved in myeloid cell development, including NFI-A [13] , LMO2-L/-S isoforms and CEBP-β (reported herein). Our data here revealed an miR-223-CEBP-β-LMO2-miR-142 regulatory pathway and a functional relationship between miR-223 and miR-142 in attenuating cell proliferation (Figure 7) . The regulatory pathway from miR-223 to miR-142 is composed of several branches including LMO2-L/-S isoforms and CEBP-β. It seems complicated and redundant, but achieves a precise regulation, and the redundancy may render the pathway robust and resistant to slight fluctuations in the cellular environment.
Notably, among all these factors, LMO2 occupies in the core position of this pathway, as it directly and solely controls miR-142 expression. LMO2 was considered as an oncogene because its ectopic expression in hematopoietic cells caused T-cell leukemia [29, 30] . It can be inferred that during hematopoiesis, the miR-223-CEBP-β-LMO2-miR-142 regulatory pathway mainly functions to control cell proliferation, which is helpful for normal cell differentiation and development. If LMO2 is ectopically expressed, however, it breaks the equilibrium in this pathway, which can not be compensated for by its upstream regulatory factors. Ectopically expressed LMO2 ultimately targets miR-142 and downregulates its expression, accelerating cell proliferation and increasing the risk for leukemia. Taken together, our data embed LMO2 in a novel regulation pathway of hematopoiesis, and suggest that the oncogenic property of LMO2 might be achieved by accelerating cell proliferation through repressing miR-142.
Materials and Methods
Plasmid construct
The proximal promoter region of Lmo2-L (from -384~+119) and promoter region of LMO2-S (from -294~+332) were cloned from normal human genome, inserted into the pGL4-basic vector and confirmed by sequencing. The 3′ UTR of LMO2 and CEBP-β were cloned from human peripheral blood cDNA, sequenced and inserted into the pGL3-control vector at the Xba I site. LMO2-L, LMO2-S and CEBP-β expression vectors were constructed by amplification of their relevant coding sequences from human peripheral blood cDNA and inserting into pcDNA3.1(+) vector. miR-142 and miR-223 expression sequences were cloned from human peripheral blood cDNA. The length of these fragments was as previously reported [12] . Such fragments were inserted into the pSilencer4.1-CMV neo vector (Ambion, CA, USA) and confirmed by sequencing. Primers used for cloning are supplied as Supplementary Information, Table S3 . si-LMO2-L/-S construct was generated as follows: DNA templates for siRNA targeting to human LMO2-L/-S mRNAs were synthesized and cloned into pSilencer 4.1-CMV neo vector (Ambion). The target sequence of the siRNAs was 5′-TCA GGG GTT TTC TTC CCC T-3′.
Cell culture and transfection
K562 and U937 cells were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum (GIBCO BRL, Grand Island, NY, USA), 100 μg/ml penicillin and 100 μg/ml streptomycin. HEK293 cells were cultured in DMEM with 10% fetal bovine serum (GIBCO), 100 μg/ml penicillin and 100 μg/ml streptomycin. Electroporation of K562 and U937 cells was performed as follows: 2 × 10 6 K562/U937 cells were resuspended in 200 μl RPMI 1640 medium without serum or antibiotics, and mixed with 10 µg total plasmid DNA. Electroporation was performed with Gene Pulser® (Bio-Rad, Hercules, CA, USA) using the following parameters: exponential wave, 210 V, 950 μF, 4 mm cassette.
CEBP-β cell types were generated by G418 selection: K562 cells were transfected with relative expression vector by electroporation. The transfected cells were resuspended in RPMI 1640 medium with 400 μg/ml G418 24 h after electroporation and cultured for 30 days. The expression of miR-142/miR-223 was confirmed by RT-PCR. HEK293 cells for transfection were plated at 1 × 10 
RNA isolation, RT-PCR and real-time PCR
Total RNA was isolated from cells using Trizol reagent (Invitrogen). 1.5 μg of each sample was used for reverse transcription by M-MLV (Promega, Madison, WI, USA), followed by PCR and real-time PCR detection. Real-time PCR was performed with the ABI PRISM 7000 (ABI, USA), using 1× Evagreen dye and ROX 
Western blot analysis
Cells were lysed by mRIPA (50 mmol/L Tris-HCl pH 7.5, 150 mmol/L NaCl, 1% Triton X-100, 0.5% DOC, 10 μg/mL Aprotinin, 10 μg/mL Leupeptin, 1 mmol/L PMSF). Total protein concentration was measured with the BCA Protein Assay Kit (Pierce Biotechnology, Rockford, IL, USA). A total of 60 μg of each sample was subjected to SDS-PAGE. After fractionation, the proteins were transferred to a nitrocellulose membrane, and they were detected using an anti-CEBP-β polyclonal antibody (Santa Cruz, CA, USA). Immunostaining was detected using an enhanced chemiluminescence system (Amersham Pharmacia Biotech, Buckinghamshire, UK).
Luciferase assay
Co-transfection into HEK293 cells of the pGL3-control-LMO2 3′ UTR or the pGL3-control-CEBP-β 3′ UTR with the pSilencer4.1-neo vector or the pSilencer4.1-miR-223 expression vector occurred at a ratio of 1:2, and the ratio between the Luciferase reporter and Renilla was 5:1. The ratio between the LMO2-L or LMO2-S promoter reporter and the CEBP-β expression vector was 1:1 for the co-transfection into HEK293 cells. The ratio between the p142 Luciferase reporter, the CEBP-β expression vector and Renilla was 5:5:1 in a total of 10 μg for electroporation of K562 cells. Cells were lysed 24 h after transfection. The Luciferase activity was measured using the Dual-Luciferase Reporter Assay Kit (Promega) and normalized to the Renilla luciferase activity, according to the manufacturer's instructions.
Site-directed mutation
Mutation of relevant sites in the pGL3-control-LMO2/CEBP-β 3′ UTR and pGL4-LMO2-L/S promoter was performed using the Stratagene QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA) following the manufacturer's instructions. The primers used to generate the mutations are supplied in the Supplementary Information, Table S1 . Efficient mutations were confirmed by sequencing.
5′-Full RACE
Total RNA from K562 cells stably expressing miR-223 was extracted using Trizol reagent (Invitrogen). 2 μg RNA was then used for 5′-RACE with the TaKaRa 5′-Full RACE Kit (TaKaRa, Dalian, China). Total RNAs were first treated with Calf Intestine Phosphatase (CIP) to remove the 5′ phosphate of non-capped RNAs, then a decap procedure was performed for the 5′ full length capped mRNAs, producing a 5′ phosphate on these RNAs. Next, ligation with RACE adaptor (a kit component) was performed to allow the 5′ full length mRNAs to be ligated. These samples were then reverse-transcribed by M-MLV (Promega) and used as template for nested PCR in which the inner and outer forward primers (kit components) were matched with the adaptor and reverse primers designed specifically according to the pre-miR-142 sequence.
The parameters for the first round of PCR were 95 ºC for 30 s, 55 ºC for 30 s, 72 ºC for 4 min, 20 cycles and for the second round of PCR were 95 ºC for 30 s, 65 ºC for 30 s, 72 ºC for 4 min, 35 cycles. Specific downstream primers for RACE are listed in the Supplementary Information , Table S5 . The PCR product was cloned into the pMD19-T vector (TaKaRa) and sequenced.
Chromosome immunoprecipitation (ChIP) assay
× 10
6 K562 cells were harvested for a ChIP assay using the Millipore Chromosome Immunoprecipitation Assay Kit (Millipore, Billerica, MA, USA). A total of 1 × 10 6 cells was lysed with 100 μL SDS Lysis Buffer (a kit component), sonicated at 40 W, 10 s each time for 6 times. These samples were diluted in 10 times their volume of Dilution Buffer (a kit component). After pre-clearing with protein G beads (75 μL per sample), the samples were incubated with the anti-CEBP-β antibody or the anti-β-actin antibody as negative a control at 4 ºC over night with rotation, and then incubated with protein G beads (60 μL per sample) for 1 h. After stringent washing with Low Salt, High Salt, LiCl and TE buffers (kit components), the DNA fragments that bound to the protein G beads were eluted with Elution Buffer containing 0.1 M NaHCO 3 and 1% SDS. These samples as well as the cell lysates used as inputs were concentrated and used as the templates for PCR analysis. Primers used for detection are listed in the Supplementary information, Table S4 . The PCR amplification parameters were 95ºC for 3 min, followed by 95 ºC for 30 s, 58 ºC for 30 s and 72 ºC for 45 s, 35 cycles.
CCK-8 cell proliferation assay
The assay was performed using the DOJINDO Cell Counting Kit-8 (DOJINDO, Gathersburg, Maryland, USA) according to the manufacturer's instructions. K562, K562
miR-142 and K562 miR-223 cells were first cultured in a series of known quantities (1 × 10 3 -1.6 × 10 4 in 2 fold linear) in 96-well plates and used for establishing their absorbance-cell number standard curves. Then, the cells were cultured in normal medium and the absorbance at 450 nm was determined every 24 h. The total number of each kind of cell was calculated according to the standard curve.
BrdU incorporation labeled cell proliferation assay
All cells used for this assay were cultured in a density of about 5 × 10 5 /ml, and BrdU (Sigma, St Louis, USA) in a final concentration of 10 μmol/L was added into the medium 1 h before harvest of cells. Collected cells were washed by PBS twice and fixed with 75% ethanol at -20ºC for 24 h. Fixed cells were then treated with 2 M HCL for 30 min and 0.1 M Na 2 B 4 O 7 for 2 min at room temperature. The anti-BrdU monoclonal antibody (Santa Cruz) was diluted in Washing Solution (PBS supplied with 0.5% BSA) in a ratio of 1:200 and incubated with cell samples for 1.5 h. After washing, the samples were incubated with the Flour 488-conjugated anti-mouse IgG antibody (Invitrogen) (1:200 dilution in Washing Solution) for 1 h. These samples were then washed and stained with PI (final concentration 50 μg/ml with 20 μg/ml RNaseA) and analyzed by a two-gated flow cytometer.
